Who is sponsoring NCT03501433?

NCT03501433 is sponsored by Iowa State University.

What drugs are being tested in NCT03501433?

Interventions in NCT03501433: Nicotinamide riboside chloride (Niagen), Placebo.

What condition does NCT03501433 study?

NCT03501433 studies Aging, Lipemia.

Is NCT03501433 still recruiting?

NCT03501433 is currently completed. Last updated 25 September 2020.

Last reviewed 2020-09-25 · How we verify

NCT03501433

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

Completed NA Last updated 25 September 2020

What this trial tests

NA trial testing Nicotinamide riboside chloride (Niagen) in Aging in 16 participants. Completed in 1 December 2019.

Timeline

1 February 2018

Primary endpoint
1 December 2019

1 December 2019

Quick facts

Lead sponsor	Iowa State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	16
Start date	1 February 2018
Primary completion	1 December 2019
Estimated completion	1 December 2019
Sites	1 location across United States

Drugs / interventions tested

Nicotinamide riboside chloride (Niagen)
Placebo

Conditions studied

Aging — all drugs for Aging →
Lipemia — all drugs for Lipemia →

Sponsor

Iowa State University

Who can join

Adults 18 to 75, any sex, with Aging or Lipemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cellular Compartmentation and the Redox/Nonredox Functions of NAD<sup>.</sup>
Kulkarni CA, Brookes PS. · · 2019 · cited 45× · PMID 30784294 · DOI 10.1089/ars.2018.7722
Impact of NAD+ metabolism on ovarian aging.
Liang J, Huang F, Song Z, Tang R, et al · · 2023 · cited 30× · PMID 38041117 · DOI 10.1186/s12979-023-00398-w
The Potential Use of Metabolic Cofactors in Treatment of NAFLD.
Mardinoglu A, Ural D, Zeybel M, Yuksel HH, et al · · 2019 · cited 29× · PMID 31336926 · DOI 10.3390/nu11071578
Roles of NAD<sup>+</sup> in Health and Aging.
Lautrup S, Hou Y, Fang EF, Bohr VA. · · 2024 · cited 28× · PMID 37848251 · DOI 10.1101/cshperspect.a041193
Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop.
Espinoza SE, Khosla S, Baur JA, de Cabo R, et al · · 2023 · cited 19× · PMID 37325957 · DOI 10.1093/gerona/glad034
NAD+ metabolism and cardiometabolic health: the human evidence.
Abdellatif M, Baur JA. · · 2021 · cited 14× · PMID 34320167 · DOI 10.1093/cvr/cvab212
Cancer treatment-induced NAD+ depletion in premature senescence and late cardiovascular complications.
Banerjee P, Olmsted-Davis EA, Deswal A, Nguyen MT, et al · · 2022 · cited 8× · PMID 35801078 · DOI 10.20517/jca.2022.13
NAD+ metabolism and therapeutic strategies in cardiovascular diseases.
Shi C, Wen Z, Yang Y, Shi L, et al · · 2024 · cited 7× · PMID 38974325 · DOI 10.1016/j.athplu.2024.06.001

Verify or expand the search:

Other recruiting trials for Aging

Currently open trials in the same condition.

NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging · recruiting
NCT07504068 — Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in · NA · recruiting
NCT07525453 — Effects of Three Different Exercise Programs on Dynamic Balance in Community-Dwelling Older Adults · NA · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Iowa State University trials

Trials by the same sponsor.

NCT06630312 — Glycemic Response of Whole Beans and Bean Products · EARLY_PHASE1 · completed
NCT05693025 — Evaluation of the Walk With Ease Program for Fall Prevention · Phase 1, PHASE2 · recruiting
NCT05762380 — Effect of Iron Supplements on the Growth of Enteric Pathogens · NA · completed
NCT05695365 — Feasibility of Resistance Exercise to Treat Major Depression Via Cerebrovascular Mechanisms · NA · completed
NCT05213000 — Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03501433 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Iowa State University
Last refreshed: 25 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03501433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing